Editor-We thank Dr Nair for the comments regarding our review of predictors of chronic pain following knee arthroplasty. 1 The main suggestion raised was the inclusion of studies that used potentially neuromodulating agents in the perioperative period (e.g. gabapentin, pregabalin, tricyclic antidepressants). Our review focused on studies within specified criteria and those that did not fulfil these criteria were not included. We agree that the influence of these agents is of interest, but at present data are lacking to provide solid evidence-based strategies. The findings from such studies are inconsistent and have focused almost exclusively on short-term outcomes. The pregabalin study by Buvanendran and colleagues 2 was not included in our metanalysis because it did not provide a global measure of pain outcome more than 3 months after TKA. Instead, their study focused only on the presence of neuropathic pain using a self-reported screening tool (S-LANSS). The authors reported a 6 month incidence of neuropathic pain of 0 and 5.2% in the pregablin and control groups, respectively. Although these results are promising, the exclusive focus on neuropathic pain is questionable given that only 13% of peristent pain after TKA is thought to be neuropathic in origin. 3 Furthermore, these findings have not been replicated, 4 and subsequent studies promoting the use of gabapentinoids have been of limited design to make any meaningful assessment on the long-term effects of these agents. 5 6 The importance of pharmacological intervention to prevent long-term pain has long been a holy grail for pain medicine, yet to date it seems that a unidimensional approach is flawed. Our review supports a multidisciplinary model of care. Modification of important psychological, behavioural, surgical, and pharmacological factors will need to be addressed to make meaningful progress in reducing this important long-term complication. 7 
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